Intravitreal anti-vascular endothelial growth factor (VEGF) agents have transformed care for many vitreoretinal disorders, allowing visual improvement or stability in diseases with previously poor visual outcomes, such as age-related macular degeneration (AMD) with associated choroidal neovascularization (CNV). Here, VEGFA is linked to choroidal neovascularization.